Abstract
5020Background: Immune checkpoint blockade has shown clinical benefit in mismatch repair deficient (dMMR) cancers, leading to accelerated FDA approval of pembrolizumab, a PD1-targeting agent, for t...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
